Description
Background:
Vantictumab Vantictumab, is a monoclonal antibody that targets a protein called Frizzled homolog 7 (FZD7). FZD7 is a receptor involved in the Wnt signaling pathway, which plays a role in various cellular processes including cell growth and development. By targeting FZD7, vantictumab aims to disrupt the Wnt signaling pathway in certain types of cancer cells.Vantictumab has been primarily studied in the context of solid tumors, including breast cancer, pancreatic cancer, and lung cancer. It has been investigated both as a standalone therapy and in combination with other anti-cancer agents. a human IgG2 monoclonal antibody designed for the treatment of cancer.
Intended Use:
For Estimation of Vantictumab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!